BG100702A - Device and method for the antagonization of the toxic effect of lidocaine on the central and the vegitative nervous system - Google Patents
Device and method for the antagonization of the toxic effect of lidocaine on the central and the vegitative nervous systemInfo
- Publication number
- BG100702A BG100702A BG100702A BG10070296A BG100702A BG 100702 A BG100702 A BG 100702A BG 100702 A BG100702 A BG 100702A BG 10070296 A BG10070296 A BG 10070296A BG 100702 A BG100702 A BG 100702A
- Authority
- BG
- Bulgaria
- Prior art keywords
- lidocaine
- toxic effect
- application
- vegitative
- antagonization
- Prior art date
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
According to this invention the antagonization of the toxiceffect of Lidocaine is attained by the application ofgalantaminechidrobromine (the Nivalin preparation) as an antidoteof Lidocaine. The method for the neutralization of the toxiceffect of Lidocaine on the central and the vegitative nervoussystem consists in fractioned subcutaneous or intravenousapplication of Nivalin at initial dose of 2.5 mg until theachievement of optical therapeutical effect - completeantagonization of the toxic effect of Licodaine. The use ofNivalin for controlling the toxic effect of Lidocaine removes anynecessity for the application of other preparations having adverseeffect on the patient in this state, and for endotrachealintubation and equipment ventilation. The preparation has an easyand convenient scheme of application with the potentials ofcontrolling the critical situation without having any need forspecial complex and expensive equipment and/or specially trainedstaff for resuscitation operations.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BG100702A BG61992B1 (en) | 1996-07-05 | 1996-07-05 | Device for the antagonization of the toxic effect of lidocaine on the central and the vegitative nervous system |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BG100702A BG61992B1 (en) | 1996-07-05 | 1996-07-05 | Device for the antagonization of the toxic effect of lidocaine on the central and the vegitative nervous system |
Publications (2)
Publication Number | Publication Date |
---|---|
BG100702A true BG100702A (en) | 1998-01-30 |
BG61992B1 BG61992B1 (en) | 1998-12-30 |
Family
ID=3926646
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG100702A BG61992B1 (en) | 1996-07-05 | 1996-07-05 | Device for the antagonization of the toxic effect of lidocaine on the central and the vegitative nervous system |
Country Status (1)
Country | Link |
---|---|
BG (1) | BG61992B1 (en) |
-
1996
- 1996-07-05 BG BG100702A patent/BG61992B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
BG61992B1 (en) | 1998-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CS553490A3 (en) | Transdermal therapeutic system | |
HUT76258A (en) | Compositions comprising dna damaging agents and p53, and methods for uses thereof | |
AU578428B2 (en) | Trace-labeled conjugates of metallothionein and target- seeking biologically active molecules | |
EP1806131A3 (en) | Use of sex steroid function modulators to treat wounds and fibrotic disorders | |
AU7289694A (en) | Three part device for the transdermic administration of drugs by electrophoresis or iontophoresis | |
MY111188A (en) | Improvements in or relating to benzothiophenes. | |
AU7545594A (en) | Implantable device for the treatment of aedemas | |
MX9605650A (en) | Fluticasone propionate formulations. | |
TW250435B (en) | ||
ES2176415T3 (en) | USE OF A COMPOSITION THAT INCLUDES A POLYMER SYSTEM. | |
MX9704030A (en) | 2-heterocyclyloxy and thiomethyl-1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof. | |
IL112029A (en) | Raloxifine and related compounds for use as medicaments for the treatment of disorders associated with an excess of tachykinin | |
MX9704037A (en) | 2-substituted 1,2,5-thiadiazolidin-3-one 1,1-dioxides and compositions and method of use thereof. | |
WO1997003188A3 (en) | Use of mp52 or mp121 for treating and preventing diseases of the nervous system | |
WO1997004788A3 (en) | Use of calendula glycosides for the treatment of psoriasis | |
MXPA94009086A (en) | Therapeutic substituted guanidines. | |
IT1290781B1 (en) | ACTIVE THERAPEUTIC AGENT FOR THE TREATMENT OF NEURONAL DEGENERATIVE DISEASES. | |
EP0744176A3 (en) | Methods for inhibiting bone loss | |
BG102667A (en) | Diosgenine-containing composition | |
AU3439799A (en) | Immunization against and treatment for infection by (h.pylori) | |
BG102716A (en) | Method for the treatment of cardiac insufficiency by means of formulations opposing the endotheline | |
BG100702A (en) | Device and method for the antagonization of the toxic effect of lidocaine on the central and the vegitative nervous system | |
NZ324615A (en) | Method for treating autism using olanzapine | |
NO953003L (en) | Use of ifenprodil and its diastereoisomers for the preparation of medical preparations | |
ES2136605T3 (en) | ELECTRICAL DEVICE FOR THE TRANSDERMIC APPLICATION OF PHARMACS WITH A COUNTERRESPECT AGENT. |